Geron GERN AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value

AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value at other companies

Tango TherapeuticsTNGX

——

ExelixisEXEL

——

Gilead SciencesGILD

——

Other financials

Income statement

See full

Revenue$51.8M+30.9%

Operating income$158.0K+101%

Net income-$3.6M+81.6%

EPS (diluted)-$0.01+66.7%

Balance sheet

See full

Cash & equivalents$48.7M-12.2%

Total debt$134.0M+10.0%

Total equity$229.1M-14.6%

Total assets$534.1M-5.0%

Cash flow

See full

Operating cash flow-$62.9M-31.1%

CapEx$206.0K+2.0%

Free cash flow-$43.8M-6.8%

Valuation

See full

Market cap$878.88M-8.6%

Enterprise value$964.15M-6.2%

P/S4.7×-172×

Profitability

See full

Operating margin-705.5%-351pp

Net margin-682.5%-339pp

FCF margin-734.4%-365pp

Returns & leverage

See full

Return on equity-27.1%-7.8pp

Debt / equity0.6×+0.1×

Current ratio6.8×-1.1×

Where this comes from

Reported directly by Geron in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's afs and trading securities - unrealized loss position (<12 months) fair value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Geron's AFS and trading securities - unrealized loss position (<12 months) fair value?: Geron (GERN) reported AFS and trading securities - unrealized loss position (<12 months) fair value of $170.93M in Q1 2026.
How has Geron's AFS and trading securities - unrealized loss position (<12 months) fair value changed year-over-year?: Geron's AFS and trading securities - unrealized loss position (<12 months) fair value increased by 93.4% year-over-year, from $88.37M to $170.93M.